ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB

ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB

The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms. L'invention concerne essentiellement des formes galéniques orales comprenant un inhibiteur de kinas...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SIEVERT, FRANK, STEFAN, RALPH
Format: Patent
Sprache:eng ; fre
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator SIEVERT, FRANK
STEFAN, RALPH
description The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms. L'invention concerne essentiellement des formes galéniques orales comprenant un inhibiteur de kinase JAK, de préférence du Ruxolitinib, appropriées pour une libération modifiée, et des procédés de préparation de telles formes galéniques orales.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2014016396A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2014016396A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2014016396A13</originalsourceid><addsrcrecordid>eNrjZLD1D3L0UXDxD3Z0d1Vw8w_yDQaRCr7-Lp5unq4uCkGuPq6Owa4Kzv6-AUGewZ5-7gpBoRH-Pp4hnn6eTjwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jA0MTA0MzY0szR0Jg4VQDXbSrZ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB</title><source>esp@cenet</source><creator>SIEVERT, FRANK ; STEFAN, RALPH</creator><creatorcontrib>SIEVERT, FRANK ; STEFAN, RALPH</creatorcontrib><description>The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms. L'invention concerne essentiellement des formes galéniques orales comprenant un inhibiteur de kinase JAK, de préférence du Ruxolitinib, appropriées pour une libération modifiée, et des procédés de préparation de telles formes galéniques orales.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2014</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140130&amp;DB=EPODOC&amp;CC=WO&amp;NR=2014016396A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20140130&amp;DB=EPODOC&amp;CC=WO&amp;NR=2014016396A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>SIEVERT, FRANK</creatorcontrib><creatorcontrib>STEFAN, RALPH</creatorcontrib><title>ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB</title><description>The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms. L'invention concerne essentiellement des formes galéniques orales comprenant un inhibiteur de kinase JAK, de préférence du Ruxolitinib, appropriées pour une libération modifiée, et des procédés de préparation de telles formes galéniques orales.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2014</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLD1D3L0UXDxD3Z0d1Vw8w_yDQaRCr7-Lp5unq4uCkGuPq6Owa4Kzv6-AUGewZ5-7gpBoRH-Pp4hnn6eTjwMrGmJOcWpvFCam0HZzTXE2UM3tSA_PrW4IDE5NS-1JD7c38jA0MTA0MzY0szR0Jg4VQDXbSrZ</recordid><startdate>20140130</startdate><enddate>20140130</enddate><creator>SIEVERT, FRANK</creator><creator>STEFAN, RALPH</creator><scope>EVB</scope></search><sort><creationdate>20140130</creationdate><title>ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB</title><author>SIEVERT, FRANK ; STEFAN, RALPH</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2014016396A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2014</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>SIEVERT, FRANK</creatorcontrib><creatorcontrib>STEFAN, RALPH</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>SIEVERT, FRANK</au><au>STEFAN, RALPH</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB</title><date>2014-01-30</date><risdate>2014</risdate><abstract>The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms. L'invention concerne essentiellement des formes galéniques orales comprenant un inhibiteur de kinase JAK, de préférence du Ruxolitinib, appropriées pour une libération modifiée, et des procédés de préparation de telles formes galéniques orales.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; fre
recordid cdi_epo_espacenet_WO2014016396A1
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
title ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T01%3A19%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=SIEVERT,%20FRANK&rft.date=2014-01-30&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2014016396A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true